Draft guidance consultation
You can now review and comment on this draft guideline.
The consultation closes on Tuesday 08 July 2025 at 5pm.
In line with NICE’s commitment to incorporate technology appraisals (TAs) within guidelines we have incorporated the following TAs:
- Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (2023) (TA929)
- Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (2023) (TA902)
- Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (2014) (TA314)
- Ivabradine for treating chronic heart failure (2012) (TA267)
The following TAs have not been incorporated into this guideline update because this update positions these medicines in a different part of the treatment pathway to that recommended in the TAs:
- Empagliflozin for treating chronic heart failure with reduced ejection fraction (2022) (TA773)
- Dapagliflozin for treating chronic heart failure with reduced ejection fraction (2021) (TA679)
- Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (2016) (TA388)
However, the status of the TAs remains unchanged. NICE is currently engaging with an advisory Stakeholder Panel to inform development of our approach to incorporation.
How to comment
1. Register your organisation or comment as an individual
If you’re commenting for an organisation, your organisation needs to be registered as a stakeholder.
Not eligible? Contact the stakeholder organisation that most closely represents your interests and pass your comments to them.
We can accept comments from individuals. These will be considered, but you won’t get a formal response and they won’t be posted on the NICE website. Wherever possible we encourage you to submit your comments through a registered stakeholder organisation.
2. Read the consultation documents
Documents to comment on:
- Draft guideline
- Evidence reviews
- Evidence review A- Pharmalogical therapy for heart failure with reduced ejection fraction
- Evidence review B- Pharmalogical therapy for heart failure with mildly reduced ejection fraction
- Evidence review C- Pharmalogical therapy for IV iron therapy
- Evidence review D- Pharmalogical therapy for mineralocorticoid receptor antagonist therapy
- Economic report
- Equality and health inequalities assessment 4
- Supporting documentation - Methods
- Supporting documentation - Acknowledgements
- Visual Summary: core treatments for heart failure
If you want to review the economic model, please see 5. Economic models below and fill in the confidentiality form
Other information about the consultation
Developing NICE guidelines: how to get involved
- Final scope – for information
3. Add your comments
- You must use this comments form.
- You must declare any links with, or funding from, the tobacco industry
If you share similar views with another organisation, send a joint response.
Make sure you consider:
- The areas that will have the biggest impact on practice and be challenging to implement
- How to help users overcome challenges
Developing NICE guidelines: how to get involved suggests some other areas to comment on.
4. Email the form to us
Email: chfiatreatment@nice.org.uk
Deadline: Tuesday 08 July 2025 at 5pm
5. Economic model
The developer has produced an economic model to support the guideline on Chronic heart failure in adults: diagnosis and management. To receive an executable version of this model, please submit a request to chfiatreatment@nice.org.uk with a signed copy of the confidentiality acknowledgement and undertaking form.
We will then send you a link to an executable version of the economic model by email. The deadline for returning your comments is the same as for the guideline consultation: Tuesday 08 July 2025 at 5pm.
This page was last updated: